Semaglutide Side Effects and Heart Health: A Clear Guide

Step 1: Understanding what 'heart-related side effects' actually means here

When people search for semaglutide side effects and the heart, they're often worried about two quite different things: whether the medicine is harmful to the heart, and whether they'll feel palpitations or a racing pulse. Those are fair questions, and the answers are different.

The most commonly reported cardiovascular effect during treatment is a small increase in resting heart rate, typically around two to five beats per minute above baseline in trial participants. For most people that's imperceptible. It tends to be most noticeable in the first few weeks after starting or increasing a dose, then it settles.

A persistent resting heart rate above 100 beats per minute (tachycardia) is less common but should be reported to your prescriber or GP. It doesn't usually indicate serious harm, but it warrants a proper look. The NHS patient information on semaglutide lists palpitations and an increased heart rate among known side effects, and the prescribing guidance recommends monitoring for patients with existing cardiac conditions.

There is a widespread misconception that GLP-1 medicines are bad for the heart, and if you want to read about side effects from semaglutide more broadly, including how cardiovascular effects fit into the overall picture, our dedicated page covers this in detail. That doesn't mean the medicines are free from any cardiovascular effect, it means the picture is more nuanced than the worry implies.

Step 2: The cardiovascular benefit evidence, and what the UK licence says

Wegovy holds a separate UK licence for reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established heart disease and either obesity or overweight. That authorisation followed the SELECT trial, a large outcome study involving over 17,000 participants.

This is worth stating plainly, because it sits alongside the weight management licence as a distinct authorisation, not a marketing claim. The MHRA's announcements page and the wider semaglutide regulatory record reflect how closely this medicine has been studied in people with cardiac risk.

At nume, our prescribers consider your full medical history (including any cardiac history) as part of the consultation. Semaglutide for weight management is not automatically ruled out by a history of heart disease, but it does require a careful clinical conversation. The Wegovy SmPC (available on the eMC) includes specific guidance for prescribers on cardiac monitoring in higher-risk patients.

If you want to understand the broader picture of Wegovy beyond cardiovascular effects, the Wegovy overview page covers the licensed indications, dose schedule and trial evidence in full.

Step 3: When to get medical help, and what counts as urgent

Most people on semaglutide don't experience anything alarming from a cardiac standpoint. But some symptoms should not be left to resolve on their own.

Seek same-day medical help if you notice: chest pain or tightness that is new or different from anything you've felt before; a heartbeat that feels irregular, fluttering, or very rapid and doesn't settle within a few minutes; feeling faint, dizzy, or breathless alongside heart symptoms; or swelling in your legs and ankles that appears or worsens after starting treatment.

Call 999 for any chest pain that is severe, spreads to your arm or jaw, or comes with sweating or sudden breathlessness. These symptoms may have nothing to do with your medication, but they need urgent assessment.

For less urgent concerns (a heart rate that feels a bit faster than usual, occasional mild palpitations) contact your prescriber or GP for advice, or visit our page on side effect of semaglutide to help you understand whether what you're experiencing is commonly reported or worth escalating sooner. You can also report any suspected side effect through the MHRA's Yellow Card scheme, which helps regulators track how medicines perform in real-world use. It's open to patients as well as healthcare professionals, and your report genuinely contributes to ongoing safety monitoring.

The cardiovascular side effects of Wegovy page goes deeper into palpitations, the SELECT trial data, and what the monitoring guidance says for people with pre-existing conditions.

Step 4: How prescribers at nume approach cardiac history in consultations

Every consultation at nume is read by a GPhC-registered Independent Prescriber, a real clinician, not a screening tool. When your answers indicate a cardiac history, that prescriber applies clinical judgement: they may approve treatment, ask follow-up questions, recommend you discuss with your GP first, or decline where it's not appropriate.

Questions about medications you're already taking matter too. Some medicines used for heart conditions (including certain antiarrhythmics) interact with semaglutide or require closer monitoring. Our prescribers check for this as standard. If you're already on treatment elsewhere and thinking of transferring, the general semaglutide side effects page covers the full profile, including interactions and contraindications, in plain terms.

If cost or access is part of your thinking, the Wegovy cost page explains what an honest private prescription includes. And if you have questions before committing to a consultation, our FAQs cover the most common ones. When you're ready, our prescribers are available seven days a week to discuss your suitability and talk through any concerns, including your cardiac history.